Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Colorectal Neoplasms 56Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 29Neoplasm Metastasis 23Glioblastoma 23Colonic Neoplasms 23Rectal Neoplasms 19Ovarian Neoplasms 16Neoplasms 15Brain Neoplasms 12Lung Neoplasms 11Pancreatic Neoplasms 10Glioma 10Fallopian Tube Neoplasms 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Gliosarcoma 7Adenocarcinoma of Lung 7Kidney Neoplasms 6Liver Neoplasms 5Astrocytoma 5Sarcoma 4Recurrence 4Oligodendroglioma 4Melanoma 4Uterine Cervical Neoplasms 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

pembrolizumab 20atezolizumab 9Nivolumab 9Gemcitabine 9Docetaxel 5avelumab 4Mitomycin 4Carboplatin 4fludarabine 3epacadostat 3enfortumab vedotin 3Cyclophosphamide 3vofatamab 2valrubicin 2rucaparib 2pemigatinib 2durvalumab 2cabozantinib 2Standard of Care 2Sirolimus 2Radiation 2Pemetrexed 2Cisplatin 2Bevacizumab 2B701 protein, Human herpesvirus 6 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trilaciclib 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × Bevacizumab × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT03272217 2025-01-07

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Terminated
16 enrolled 12 charts
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡